ZHAOKE OPHTH-B (06622) announced a net loss of approximately 209 million yuan in 2025, a year-on-year decrease of 12%.
Zhaoke Ophthalmology-B (06622) announces its performance in 2025, with revenue of 31.974 million yuan, a year-on-year decrease of 53.88%; after-tax losses of approximately 209 million yuan, a year-on-year decrease of 12%.
ZHAOKE OPHTH-B (06622) announced its performance in 2025, with a revenue of 3197.4 million yuan, a year-on-year decrease of 53.88%; a post-tax loss of approximately 2.09 billion yuan, a year-on-year narrowing of 12%.
The announcement stated that the reduction in losses is mainly due to the group continuing to strictly control administrative expenses and sales and distribution expenses, reflecting strengthened cost control and improved operational efficiency during the year. In addition, research and development expenses have decreased with the achievement of several key development milestones, and there were no non-recurring expenses incurred as in the previous year, further driving improvement. Despite not achieving one-time licensing revenue as in the previous year, and a reduction in bank interest income due to interest rate cuts in 2025, the group's losses for the year have still substantially narrowed.
Related Articles

CT VISION (00994) issues profit warning, expecting shareholders' share of net loss for the year 2025 to be not less than HK$33 million.

WEILI HOLDINGS (02372) releases annual performance, with a net loss attributable to shareholders of 4.1 million yuan, a year-on-year decrease of 56.8%.

From turning point of profit to platform going overseas, the 2025 report reveals the advanced path of Lepubio Biopharma (02157).
CT VISION (00994) issues profit warning, expecting shareholders' share of net loss for the year 2025 to be not less than HK$33 million.

WEILI HOLDINGS (02372) releases annual performance, with a net loss attributable to shareholders of 4.1 million yuan, a year-on-year decrease of 56.8%.

From turning point of profit to platform going overseas, the 2025 report reveals the advanced path of Lepubio Biopharma (02157).






